Cadherins, contact normalization, and targeting podoplanin to treat oral cancer

钙粘蛋白、接触正常化和靶向平足蛋白治疗口腔癌

基本信息

项目摘要

Summary Oral cancer kills over 8,000 people in the USA and 120,000 people worldwide every year. In addition to this mortality, oral cancer survivors suffer from permanent sequelae and decreased quality of life. Over 90% of oral cancers are caused by oral squamous cell carcinoma (OSCC). This project is based on the premise that nontransformed cells can control the growth of neighboring transformed cells by contact normalization. Direct contact between transformed and nontransformed cells is required for this process. However, junctions responsible for contact normalization, and gene products that enable cancer cells to overcome this form of growth control, have not been defined. We found that contact normalization suppresses expression of the transmembrane mucin receptor podoplanin (PDPN) downstream of oncogenic Src tyrosine kinase activity. Many cancer cells, including OSCCs, express PDPN to promote cancer progression. Precancerous oral lesions (e.g. leukoplakia) that express high levels of PDPN are several times more likely to become cancers than lesions that do not express PDPN. In addition, PDPN has been identified as an immune cell checkpoint corepressor. Indeed, PDPN has emerged as a functionally relevant biomarker and chemotherapeutic target that can be used to detect and treat oral cancer. Our rationale is based on the fact that cadherin junctions are often disrupted between transformed cells, while PDPN expression is enhanced. PDPN antibodies and Maackia amurensis seed lectin (MASL) efficiently target PDPN to decrease OSCC cell motility and viability. Moreover, MASL is nontoxic and can be administered orally to inhibit tumor growth and vascularization without notable side effects in preclinical studies. We hypothesize that cadherins mediate contact normalization to suppress PDPN expression, and PDPN can be utilized as a functionally relevant chemotherapeutic target to synergistically inhibit tumor cell growth and augment anticancer immune response. We propose 3 Specific Aims to test this hypothesis. In Aim 1, we will determine if cadherins are needed for nontransformed cells to normalize morphology, growth, motility, Wnt signaling, and PDPN expression of adjacent Src transformed and OSCC cells. In Aim 2, we will determine if PDPN signaling enables Src transformed fibroblasts and OSCC cells to override growth control by neighboring nontransformed cells. In Aim 3, we will determine if MASL can target PDPN to augment host immune response in concert with its ability to inhibit OSCC cell growth in an FDA approved Phase 1 human clinical trial on oral cancer patients. This project will expose graduate and medical students to basic research in molecular and cell biology to elucidate fundamental mechanisms behind contact normalization. This work will enhance our abilities to detect, prevent, and treat oral cancer, as well as other cancers that are driven by PDPN signaling.
总结

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration.
Maackia amurensis seed lectin (MASL) ameliorates articular cartilage destruction and increases movement velocity of mice with TNFα induced rheumatoid arthritis.
  • DOI:
    10.1016/j.bbrep.2022.101341
  • 发表时间:
    2022-12
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Hamilton, Kelly L.;Greenspan, Amanda A.;Shienbaum, Alan J.;Fischer, Bradford D.;Bottaro, Andrea;Goldberg, Gary S.
  • 通讯作者:
    Goldberg, Gary S.
Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells.
  • DOI:
    10.1186/s12964-021-00817-9
  • 发表时间:
    2022-02-17
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Sheehan SA;Retzbach EP;Shen Y;Krishnan H;Goldberg GS
  • 通讯作者:
    Goldberg GS
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GARY S GOLDBERG其他文献

GARY S GOLDBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GARY S GOLDBERG', 18)}}的其他基金

The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
  • 批准号:
    6917827
  • 财政年份:
    2005
  • 资助金额:
    $ 48.3万
  • 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
  • 批准号:
    7109343
  • 财政年份:
    2005
  • 资助金额:
    $ 48.3万
  • 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
  • 批准号:
    6785502
  • 财政年份:
    2003
  • 资助金额:
    $ 48.3万
  • 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
  • 批准号:
    7073631
  • 财政年份:
    2003
  • 资助金额:
    $ 48.3万
  • 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
  • 批准号:
    6923578
  • 财政年份:
    2003
  • 资助金额:
    $ 48.3万
  • 项目类别:
Transfer of Metabolites through Lens Gap Junctions
通过晶状体间隙连接转移代谢物
  • 批准号:
    6576040
  • 财政年份:
    2003
  • 资助金额:
    $ 48.3万
  • 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
  • 批准号:
    6780978
  • 财政年份:
    2002
  • 资助金额:
    $ 48.3万
  • 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
  • 批准号:
    6540944
  • 财政年份:
    2002
  • 资助金额:
    $ 48.3万
  • 项目类别:
The Src Kinase, cell communication & growth control
Src 激酶,细胞通讯
  • 批准号:
    6605626
  • 财政年份:
    2002
  • 资助金额:
    $ 48.3万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 48.3万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 48.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了